Decreasing Agitation in Patients With Dementia Through the Use of Weighted Blankets

Sponsor
Mayo Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT03643991
Collaborator
(none)
30
1
2
58.6
0.5

Study Details

Study Description

Brief Summary

Hospitalized patients with dementia and aggression and/or agitation will be given a weighted blanket to see if there are significant reductions in agitated and aggressive behaviors compared to treatment as usual.

Condition or Disease Intervention/Treatment Phase
  • Other: Weighted Blanket
N/A

Detailed Description

The Intervention Group (Cohort 1 - first 15 patients to be enrolled):
  1. Patient or Legally Authorized Representative (LAR) will be asked to sign a consent form and will have the study explained.

  2. Nursing staff will complete baseline assessments to measure behavioral disturbances using the CMAI and CGI and other distressing symptoms using the ESAS-r.

  3. A weighted blanket, based on admission body weight, will be provided to the patient under nursing supervision.

  4. For 3 consecutive days after each use of weighted blanket, nursing staff will complete morning assessments to measure behavioral disturbances using the CMAI and CGI and other distressing symptoms using the ESAS-r.

  5. At the end of the intervention, nursing staff will complete post-intervention assessments to measure behavioral disturbances using the CMAI and CGI and other distressing symptoms using the ESAS-r.

Control Group (Cohort 2 - second 15 patients to be enrolled):
  1. Patient or Legally Authorized Representative (LAR) will be asked to sign a consent form and will have the study explained.

  2. The study team will recruit a group of patients with similar characteristics as described in the inclusion criteria; however, the patient will not receive the weighted blanket, but undergo the same assessments as described in 1-5 (above) and in the Schedule of Assessments.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
First 15 subjects enrolled in the study will be given the weighted blanket treatment and the second 15 subjects will be a control cohort.First 15 subjects enrolled in the study will be given the weighted blanket treatment and the second 15 subjects will be a control cohort.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Decreasing Agitation in Patients With Dementia Through the Use of Weighted Blankets: A Pilot Study
Actual Study Start Date :
Apr 11, 2018
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Weighted Blanket Cohort

First 15 subjects enrolled have access to sleep with weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).

Other: Weighted Blanket
Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.

No Intervention: Control Cohort

Last 15 subjects enrolled receive treatment as usual while inpatient.

Outcome Measures

Primary Outcome Measures

  1. Cohen-Mansfield Agitation Inventory Short Version (CMAI) Change [At baseline, days 1-3, and then within 72 hours of last use of the weighted blanket]

    Assess the agitation/aggression outcome using numeric scales ranging from 1-5. The sum of the scores is defined as the agitation/aggression outcome and ranges from 14-70, with the lower score being the better outcome.

Secondary Outcome Measures

  1. The revised Edmonton Symptom Assessment System Revised (ESAS-r) Change [At baseline and within 72 hours of the last use of the weighted blanket.]

    Assessment of symptoms in palliative patients using numeric analog scales ranging from 0 to 10 to assess levels of pain, tiredness, drowsiness, nausea, appetite, shortness of breath, depression, anxiety, and well-being. The sum of the scores for all symptoms is defined as the symptom distress score. The range of the sum is 0-100, with a lower score indicating a better outcome. The ESAS-r is a validated tool and publicly available for use.

  2. Clinical Global Impressions (CGI) [At baseline, days 1-3, and then within 72 hours of last use of the weighted blanket]

    Aggression/Agitation as a measure of the global clinical outcome using a numeric scale ranging from 1-7, with a lower score indicating a better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients admitted on the inpatient geriatric psychiatry unit, age 60 years and older.

  2. Diagnosis of dementia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.

  3. Presence of agitation/aggression symptoms as defined by a minimum aggression score on the Cohen-Mansfield Agitation Inventory Short Version (CMAI): a score ≥ 4 on at least one aggressive item.

Exclusion Criteria:
  1. Inability to remove blanket;

  2. Severe pain exacerbated by use of weighted blanket;

  3. Skin burns or open wounds;

  4. Allergy to blanket material.

  5. Admitted on 72 hour hold.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Janette C Leal, M.D, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Janette C. Leal, Principle Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT03643991
Other Study ID Numbers:
  • 17-009951
First Posted:
Aug 23, 2018
Last Update Posted:
May 12, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Janette C. Leal, Principle Investigator, Mayo Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 12, 2022